OncoSure sought to offer direct-to-consumer cancer screening via an at-home, non-invasive blood collection subscription service, utilising machine learning to detect circulating cfDNA methylation signatures for over 50 cancer types. After reaching the MedTech Actuator Origin Semi-Finals in October 2022 and refining their business plan, our co-founders paused the project to focus on their respective research degrees.
Company Details
Oncosure Questions
Oncosure's LinkedIn profile is https://au.linkedin.com/company/oncosure
Oncosure has
1 employees.
View email and phone details for 1
employees at Oncosure.
Oncosure's industry is
Medical and Diagnostic Laboratories
Oncosure's top competitors are
Ai Skunkworks At Northeastern University,
Nu Sanskriti,
Oncoindia,
Integen Llc,
Grande Giove,
Oncosure Testing Laboratory,
Nexus Diagnostics,
Integenx, Inc.,
Envi Medical,
Pretect Devices Pty Ltd.
Oncosure's categories are Medical and Diagnostic Laboratories
Oncosure's founding year is 2022
